Kazia Therapeutics Limited Private Placement

SEC Filing 6-K (0001193125-25-171004)

Kazia Therapeutics Limited entered into a securities purchase agreement on July 31, 2025, for a private placement of equity securities. The company agreed to sell 14,204,500 ordinary shares at $0.0176 per share and pre-funded warrants to purchase up to 204,547 American Depositary Shares (ADSs) at $8.7999 per warrant. Each ADS represents 500 ordinary shares. The pre-funded warrants are immediately exercisable at $0.0001 per ADS and will expire when fully exercised. The private placement is expected to close on or about August 4, 2025, with net proceeds estimated at approximately $2 million. The proceeds will support the clinical development of the company's lead programs, including paxalisib and EVT801, and for general corporate purposes. The shares and warrants were offered without registration under the Securities Act, relying on exemptions provided by Section 4(a)(2) and Rule 506. The company has agreed to file a registration statement to register the shares and ADSs for resale within 60 days of the closing.